このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

The Pediatric Sleep Study

2026年11月16日 更新者:Olly, PBC

A Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Impact of a Dietary Gummy on Sleep Outcomes in Children Aged 4-16 With Parent/Guardian-Reported Sleep Concerns

The goal of this clinical trial is to learn if a melatonin-free sleep gummy (a chewable dietary supplement) improves sleep in children aged 4 to 16 whose parents report sleep concerns. It will also learn about the safety and tolerability of the gummy. The main questions it aims to answer are:

  1. Does the gummy improve the child's sleep disturbance, compared with a look-alike gummy?
  2. Does the gummy change daytime problems linked to poor sleep, sleep habits, and the parent's overall impression of the child's sleep?
  3. What medical problems do children have when taking the gummy?

Researchers will compare the sleep gummy to a placebo (a look-alike gummy that contains no active ingredient) to see if the sleep gummy improves sleep.

Participants will:

  1. Complete about 1 week of baseline questionnaires and diaries, then take 2 gummies once a day in the evening for 4 weeks, with a parent or guardian supervising
  2. Take part from home, with no clinic visits, using the Chloe study app
  3. Answer sleep questionnaires every week, a sleep habits questionnaire every 2 weeks, and a safety survey every week
  4. Have a parent or guardian keep a daily diary of sleep, naps, mood, activity, and the time the gummies were taken
  5. Some participants (an optional group of 60) will also wear a wrist device (a fitness tracker/smartwatch) at night to measure sleep

調査の概要

状態

募集

条件

介入・治療

詳細な説明

Each family takes part for up to about 11 weeks in total which includes a 1 week baseline period and a 4 week study product/placebo use period.

研究の種類

介入

入学 (推定)

200

段階

  • 適用できない

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

研究場所

    • California
      • Los Angeles、California、アメリカ、90045
        • 募集
        • People Science, Inc.
        • 主任研究者:
          • Noah Craft, MD, PhD
        • コンタクト:
        • 副調査官:
          • Marie C Erfe, MD

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

4年~16年 (子)

健康ボランティアの受け入れ

はい

受講資格のある性別

全て

説明

Inclusion Criteria:

  • Child is aged 4 to 16 years, inclusive, at screening.
  • Parent or legal guardian reports current concerns about the child's sleep (for example, difficulty falling asleep, staying asleep, or keeping a consistent sleep routine) and confirms the child has no diagnosed sleep disorder.
  • Parent or legal guardian can read and understand English.
  • Parent or legal guardian can read, understand, and give informed consent on behalf of the child; the child gives age-appropriate assent where applicable.
  • Parent or legal guardian can use a personal smartphone and download Chloe by People Science.
  • Parent or legal guardian can receive shipment of the study product or placebo, and any wearable device, at an address within the United States.
  • Parent or legal guardian can support the child in completing study assessments for up to 11 weeks.
  • Child is willing and able to consume the gummy and can safely chew and swallow gummy products.
  • Parent or legal guardian agrees to keep the child's current lifestyle, diet, bedtime routine, and physical activity for the whole study.
  • Child has a regular sleep-wake cycle with a consistent bedtime and wake time (within about 1 hour on weekdays and weekends) for at least 3 weeks before baseline, and agrees to keep this schedule during the study.

Exclusion Criteria:

  • No personal smartphone, no internet access, or unwilling to download Chloe.
  • Child has a diagnosed sleep disorder needing medical management (for example, obstructive sleep apnea, narcolepsy, or restless leg syndrome).
  • Child snores loudly on most nights, has been seen to stop breathing, gasp, or choke during sleep, or has been referred for a sleep evaluation that is not yet complete.
  • Use of melatonin, prescription sleep medication, or other sleep aids (including over-the-counter antihistamines used for sleep and CBD or hemp products) within 28 days before screening, or expected use during the study.
  • Regular caffeine intake of more than 1 caffeinated beverage (over 110 mg) per day, or unwillingness to keep caffeine intake stable and avoid caffeine after mid-afternoon.
  • Use of a standalone magnesium supplement, or any dietary supplement marketed for sleep, stress, relaxation, mood, or focus, within 30 days before randomization or during the study. A stable-dose standard children's multivitamin is allowed.
  • Any investigational therapy within 30 days before randomization.
  • Known allergy or hypersensitivity to any study product or placebo ingredient, to Asteraceae (daisy family) plants, or to soy, egg, peanut, tree nuts, shellfish, milk, wheat, or sesame.
  • Any medical, neurodevelopmental, or psychiatric condition that, in the Principal Investigator's opinion, may confound sleep outcomes or affect participation.
  • Significant illness, disease, or condition that, in the Principal Investigator's opinion, may affect participation or outcomes.
  • Unlikely to be able to comply with the study, or considered unsuited by the Principal Investigator.
  • History or presence of a clinically diagnosed neurologic, cardiac, renal, hepatic, endocrine (including diabetes), pulmonary, biliary, or gastrointestinal condition. Well-controlled asthma managed with as-needed medication, seasonal allergies, and mild eczema are not exclusions.
  • Body mass index at or above the 95th percentile for age and sex.
  • Use of angiotensin-converting enzyme inhibitors, other magnesium-retaining drugs, or potassium-sparing diuretics.
  • Other diseases or medications that might interfere with the study or put the participant's health at risk.
  • Immune insufficiency (such as selective IgA deficiency, common variable immunodeficiency, or X-linked agammaglobulinemia).
  • Taking any prescription medication or dietary supplement for anxiety, depression, mood, stress, focus, or attention-deficit/hyperactivity disorder.
  • Known liver dysfunction.
  • Use of systemic corticosteroids or immunosuppressant drugs.
  • History of cancer within the past 5 years.
  • Planned surgery or invasive medical procedures during the study.
  • Planned travel during baseline or the use period that involves a time zone change or 2 or more consecutive nights away from the usual sleep environment.
  • Parent or legal guardian cannot communicate with the study team or complete study procedures, or child has a condition that would prevent completing assent or assessments.
  • Child or household member of an employee of People Science or the Sponsor (Unilever/Olly).
  • Pregnant or breastfeeding (self-reported).
  • Another child in the same household is already enrolled.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:支持療法
  • 割り当て:ランダム化
  • 介入モデル:並列代入
  • マスキング:4倍

武器と介入

参加者グループ / アーム
介入・治療
アクティブコンパレータ:Active Product

Under parent/guardian supervision, participant takes 2 gummies once per evening for 4 weeks.

Melatonin-free supplement intended for children who experience mild-to-moderate sleep concerns. Contains magnesium, l-theanine, lemon balm extract, and chamomile.

プラセボコンパレーター:Placebo

Under parent/guardian supervision, participants 2 gummies oncer per evening for 4 weeks

The placebo gummy matches the study product in appearance, flavor, texture, and packaging and contains no active ingredients.

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Change from Baseline in Patient-Reported Outcomes Measurement Information System (PROMIS) Pediatric Sleep Disturbance T-Score
時間枠:Baseline and weekly through Week 4 of the product or placebo use period

Age-appropriate Patient-Reported Outcomes Measurement Information System (PROMIS) Pediatric Sleep Disturbance short form measuring sleep problems over the past 7 days. Each item is rated 1 to 5, and raw scores are converted to a T-score (reference population mean 50, standard deviation 10) with a possible range of 20 to 80. Higher scores mean more sleep disturbance (a worse outcome). A negative change from baseline indicates improvement.

Baseline and weekly through Week 4 of the product or placebo use period

二次結果の測定

結果測定
メジャーの説明
時間枠
Number of Participants with Adverse Events and Serious Adverse Events
時間枠:From the start to end of the study product/placebo use period through (Days 8-35)

Adverse events and serious adverse events reported by parents or guardians and assessed by the investigator.

From the start to end of the study product/placebo use period through (Days 8-35)
Change from Baseline in PROMIS Pediatric Sleep-Related Impairment T-Score
時間枠:Baseline and weekly through Week 4 of the product or placebo use period

Age-appropriate Patient-Reported Outcomes Measurement Information System (PROMIS) Pediatric Sleep-Related Impairment short form measuring the daytime effects of poor sleep (such as tiredness and trouble concentrating) over the past 7 days. Each item is rated 1 to 5, and raw scores are converted to a T-score (reference population mean 50, standard deviation 10) with a possible range of 20 to 80. Higher scores mean more sleep-related impairment (a worse outcome). A negative change from baseline indicates improvement.

Baseline and weekly through Week 4 of the product or placebo use period
Change from Baseline in Children's Sleep Habits Questionnaire (CSHQ) Total Score
時間枠:Baseline and Weeks 2 and 4 of the product or placebo use period

The Children's Sleep Habits Questionnaire (CSHQ) is a parent-completed questionnaire of children's sleep behavior. The total score is the sum of 33 items, each scored 1 to 3 (some items reverse-scored), giving a possible range of 33 to 99. Higher scores mean more sleep problems (a worse outcome). A negative change from baseline indicates improvement.

Baseline and Weeks 2 and 4 of the product or placebo use period
Parent/Guardian Global Impression of Change (PGIC-Proxy) Rating at Week 4
時間枠:Week 4 of the product or placebo use period

The Parent/Guardian Global Impression of Change (PGIC-Proxy) is a single parent- or guardian-rated item comparing the child's sleep with baseline. It uses a 7-point scale from 1 (very much improved) to 7 (very much worse), with 4 indicating no change. Lower scores mean greater improvement (a better outcome) and higher scores mean worsening (a worse outcome).

Week 4 of the product or placebo use period

その他の成果指標

結果測定
メジャーの説明
時間枠
Change from Baseline in Wearable-Derived Total Sleep Time (Minutes)
時間枠:Nightly during the baseline week and the 4-week product or placebo use period.

Mean nightly total sleep time, measured by a wrist-worn consumer wearable in the wearable substudy subset, in minutes (minimum 0, no fixed maximum). Higher values mean more sleep (a better outcome). A positive change from baseline indicates improvement.

Nightly during the baseline week and the 4-week product or placebo use period.
Change from Baseline in Wearable-Derived Sleep Onset and Offset Times (Minutes)
時間枠:Nightly during the baseline week and the 4-week product or placebo use period.

Mean nightly sleep onset time and sleep offset time (wake time), measured by a wrist-worn wearable, expressed as change in clock time in minutes between the baseline week and the use period. Positive values mean later onset or offset and negative values mean earlier onset or offset. There is no fixed minimum or maximum, and no direction is better or worse.

Nightly during the baseline week and the 4-week product or placebo use period.
Change from Baseline in Wearable-Derived Wake After Sleep Onset (Minutes)
時間枠:Nightly during the baseline week and the 4-week product or placebo use period.

Mean nightly minutes awake after initial sleep onset, measured by a wrist-worn wearable (minimum 0, no fixed maximum). Higher values mean more night-time waking (a worse outcome). A negative change from baseline indicates improvement.

Nightly during the baseline week and the 4-week product or placebo use period.
Change from Baseline in Wearable-Derived Sleep Efficiency (Percent)
時間枠:Nightly during the baseline week and the 4-week product or placebo use period.

Mean nightly sleep efficiency, defined as total sleep time divided by time in bed, as a percentage (0 to 100), measured by a wrist-worn wearable. Higher values mean better sleep efficiency (a better outcome). A positive change from baseline indicates improvement.

Nightly during the baseline week and the 4-week product or placebo use period.
Change from Baseline in Wearable-Derived Number of Awakenings
時間枠:Nightly during the baseline week and the 4-week product or placebo use period.

Mean number of awakenings per night, measured by a wrist-worn wearable (minimum 0, no fixed maximum). Higher counts mean more fragmented sleep (a worse outcome). A negative change from baseline indicates improvement.

Nightly during the baseline week and the 4-week product or placebo use period.

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

協力者

捜査官

  • 主任研究者:Noah Craft, MD, PhD、People Science, Inc.

出版物と役立つリンク

研究に関する情報を入力する責任者は、自発的にこれらの出版物を提供します。これらは、研究に関連するあらゆるものに関するものである可能性があります。

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (推定)

2026年11月13日

一次修了 (推定)

2027年6月1日

研究の完了 (推定)

2027年7月1日

試験登録日

最初に提出

2026年11月5日

QC基準を満たした最初の提出物

2026年11月5日

最初の投稿 (実際)

2026年11月12日

学習記録の更新

投稿された最後の更新 (実際)

2026年11月19日

QC基準を満たした最後の更新が送信されました

2026年11月16日

最終確認日

2026年11月1日

詳しくは

本研究に関する用語

その他の研究ID番号

  • OLY-KDS-0008
  • PS60 (その他の識別子:People Science)

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

いいえ

IPD プランの説明

Only coded, de-identified data are delivered to the sponsor. Identifiable data are not shared with the sponsor or any third party. Any release of study data to third parties requires written approval of the Principal Investigator.

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。